Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference [Yahoo! Finance]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Yahoo! Finance
biodistribution preclinically and validated clinically, enabling meaningful cardiac delivery at relatively low doses with a favorable safety profile. Lead FA candidate LX2006 has shown dose-responsive, consistent reductions in LVMI and marked troponin declines alongside increased cardiac frataxin on biopsy; Lexeo is pursuing an accelerated FDA pathway targeting 10% LVMI improvement and expects pivotal results in early 2026. LX2020 (PKP2-ACM) has produced dose-dependent increases in plakophilin-2 and reductions in nonsustained VT (22% overall, up to ~60–65% in high-dose patients), with a clinical update due in Q4, and the company reports cash in the “mid $200s” with burn in the mid-$20s per quarter, providing runway into 2028. Interested in Lexeo Therapeutics, Inc.? Here are five stocks we like better. Pharma Frenzy: Volatility Ignites Biotech Sector Lexeo Therapeutics (NASDAQ:LXEO) executives outlined the company's focus on precision medicines for inherited cardiac diseases
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics to Participate in the Leerink Global Healthcare ConferenceGlobeNewswire
- Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]Seeking Alpha
- Lexeo Therapeutics to Participate in Upcoming Investor Conferences in FebruaryGlobeNewswire
- H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA TherapeuticsGlobeNewswire
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 2/20/26 - Form 4
- 2/20/26 - Form 4
- 2/20/26 - Form 4/A
- LXEO's page on the SEC website